Castle Biosciences(CSTL) - 2023 Q1 - Earnings Call Presentation

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | 2 Financial Performance Summary Q1 2023 1See Non-GAAP reconciliations at the end of this presentation. 2Year-over-year change in cash, cash equivalents and marketable securities includes the acquisition of AltheaDx in April 2022 and payout of annual bonuses in Q1 2023, among other uses. Key Q1 2023 Accomplishments Published prospective, multicenter study, called DECIDE,1 showing DecisionDx-Melanoma test resul ...